V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 210031574 | 210013939 | 1.71 | 97.7 | Disease modification (D) | 2016-10-23 | 2016-10-23 | CYTARABINE | 02 | N | 210035520 | LENALIDOMIDE |
| 210031575 | 210013940 | 1.75 | 70.4 | Disease modification (D) | 2016-07-26 | 2016-07-26 | Hydroxycarbamide | N | N | 210035533 | RCEOP |
| 210031576 | 210031598 | null | 90 | null | 2018-04-03 | 2018-08-10 | CLL210 TRIAL | N | N | 210035850 | PMITCEBO-R |
| 210031577 | 210013950 | 1.67 | 66 | null | 2014-02-15 | 2014-02-19 | FLAG | Y | N | 210036092 | OFATUMUMAB |
| 210031578 | 210013952 | 1.74 | 88.4 | Adjuvant (A) | 2017-10-25 | 2017-11-04 | FCR IV - Cycle 2 onwards | 02 | N | 210036454 | TRASTUZUMAB |
| 210031579 | 210013955 | null | 81 | Curative (C) | null | 2014-10-20 | RUXOLITINIB | Y | N | 210036485 | ABIRATERONE |
| 210031580 | 210013959 | null | null | Curative (C) | 2019-10-03 | 2019-10-03 | CARBOPLATIN + ETOPOSIDE + VINCRISTINE SULPHATE | N | N | 210036496 | CISPLATIN + GEMCITABINE + RITUXIMAB |
| 210031581 | 210013961 | null | 52.3 | Adjuvant (A) | 2019-05-16 | 2019-05-19 | CLARITY Trial | 02 | Y | 210036578 | CISPLATIN + GEMCITABINE + RITUXIMAB |
| 210031582 | 210013963 | null | 61 | Disease modification (D) | 2015-07-25 | 2015-07-25 | Sunitinib | N | null | 210036643 | ALL INDUCTION |
| 210031583 | 210013968 | 1.65 | 61 | Disease modification (D) | 2016-03-22 | 2017-03-26 | REGORAFENIB | N | N | 210036881 | UKALL 60+ TRIAL |
| 210031584 | 210028242 | 1.72 | 29.2 | Curative (C) | 2019-07-23 | 2019-07-30 | Cytarabine intrathecal | null | N | 210036916 | IRINOTECAN + MDG |
| 210031585 | 210013970 | 1.85 | 75.6 | Disease modification (D) | 2014-04-02 | 2014-04-02 | ALEMTUZUMAB + CYCLOPHOSPHAMIDE + METHOTREXATE | Y | N | 210036941 | ALL |
| 210031586 | 210013972 | 1.58 | null | Curative (C) | 2017-07-31 | 2017-07-31 | DOXORUBICIN | 01 | N | 210037146 | CYCLET |
| 210031587 | 210013975 | null | 70.8 | Curative (C) | 2013-11-14 | 2013-11-14 | CARBOPLATIN + ETOPOSIDE + VINCRISTINE SULPHATE | null | null | 210037309 | VAI |
| 210031588 | 210013977 | null | null | Palliative (P) | 2016-08-21 | 2016-08-22 | FCR IV - Cycle 2 onwards | N | N | 210037404 | CLARITY TRIAL |
| 210031589 | 210022719 | null | 81.7 | Curative (C) | 2018-11-28 | 2018-11-29 | Mitomycin Intravesical | Y | N | 210037672 | TRASTUZUMAB |
| 210031590 | 210013980 | 1.79 | 50 | Curative (C) | 2019-10-12 | 2019-10-19 | CODOX M | N | N | 210037675 | CLL210 TRIAL |
| 210031591 | 210013987 | 1.73 | 66.599 | Curative (C) | 2018-02-20 | 2018-03-07 | CYTARABINE | 2 | null | 210038079 | CYCLOPHOSPHAMIDE + ETOPOSIDE + PROCARBAZINE |
| 210031592 | 210013995 | 1.74 | 0 | Palliative (P) | 2018-08-31 | 2018-09-07 | FCR IV - Cycle 2 onwards | N | N | 210038641 | CYCLO + FLUDARABINE + RITUXIMAB |
| 210031593 | 210013996 | null | 105.9 | Palliative (P) | 2018-01-18 | 2018-02-09 | ALL UKALL2003 C: Ph VII Maintenance | null | N | 210038652 | IMMUNOGLOBULIN |
| 210031594 | 210022730 | 1.81 | 93 | Adjuvant (A) | 2015-11-23 | 2015-12-21 | ALL UKALL2003 C: Ph VII Maintenance | N | N | 210038996 | ABIRATERONE |
| 210031595 | 210014004 | 1.8 | 18.2 | Disease modification (D) | 2014-12-06 | 2014-12-06 | LENALIDOMIDE + dexamethasone | N | N | 210039065 | CYTARABINE HD + METHOTREXATE HD |
| 210031596 | 210014008 | 1.57 | 64.3 | Curative (C) | 2014-05-02 | 2014-05-22 | CYCLOPHOSPHAMIDE + ETOPOSIDE + NELARABINE | 02 | N | 210039506 | HYDROXYCARBAMIDE |
| 210031597 | 210035180 | 1.83 | 78 | Palliative (P) | 2017-09-04 | 2017-09-12 | Cyclophosphamide High Dose | null | N | 210039555 | DHAP |
| 210031598 | 210014009 | 1.85 | null | Disease modification (D) | 2016-10-01 | 2016-10-01 | CYTARABINE + ETOPOSIDE | 2 | Y | 210039663 | FLUDARABINE + MELPHALAN |
| 210031599 | 210014014 | 1.81 | 105.5 | Disease modification (D) | 2017-01-08 | 2017-10-25 | CYCLOPHOSPHAMIDE + ETOPOSIDE + VINCRISTINE | null | N | 210040040 | ABVD |
| 210031600 | 210014018 | 1.59 | 68.6 | Palliative (P) | 2018-08-18 | 2018-08-18 | DAUNORUBICIN | N | N | 210040051 | DAUNORUBICIN + VNCRISTINE |
| 210031601 | 210022736 | 1.56 | 90 | Palliative (P) | null | 2017-02-18 | DABRAFENIB + TRAMETINIB | null | Y | 210040164 | ALEMTUZUMAB + BUSULFAN + CYCLOPHOSPHAMIDE |
| 210031602 | 210014025 | null | 45.3 | null | 2017-09-11 | 2017-10-12 | Trastuzumab Subcutaneous | N | N | 210040409 | HYDROXYCARBAMIDE |
| 210031603 | 210014030 | null | 66.4 | Disease modification (D) | 2016-06-06 | 2016-06-26 | FLUDARABINE | N | null | 210040771 | FLUDARABINE + MELPHALAN |
| 210031604 | 210028260 | 1.69 | 72 | null | 2014-09-07 | 2014-10-22 | Bevacizumab + Temozolomide | Y | N | 210040788 | DASATINIB + IDARUBICIN + VINCRISTINE |
| 210031605 | 210014035 | null | 80.6 | Disease modification (D) | 2017-12-06 | 2017-12-06 | Azacitidine | N | N | 210041159 | PACKER INDUCTION VINCRISTINE + RT |
| 210031606 | 210022745 | 1.74 | 103.4 | Curative (C) | 2016-08-05 | 2017-04-01 | CARBOPLATIN + ETOPOSIDE + IFOSFAMIDE | 2 | N | 210041453 | LENALIDOMIDE |
| 210031607 | 210014045 | 0 | 90 | Palliative (P) | 2013-05-31 | 2013-06-05 | PACLITAXEL | 2 | N | 210041720 | DA |
| 210031608 | 210022748 | 1.72 | 63.3 | Curative (C) | 2017-11-21 | 2019-08-12 | CYCLOPHOSPHAMIDE + ETOPOSIDE + NELARABINE | N | N | 210041755 | ABVD |
| 210031609 | 210014050 | 1.81 | 10.7 | Curative (C) | 2018-06-01 | 2018-06-03 | CARBOPLATIN + ETOPOSIDE + IFOSFAMIDE | N | null | 210041781 | CARBOPLATIN + PACLITAXEL + RT |
| 210031610 | 210028268 | 1.77 | null | Curative (C) | 2015-12-24 | 2016-12-06 | PACLITAXEL | N | Y | 210042046 | OBINUTUZUMAB |
| 210031611 | 210022754 | 1.45 | 78.75 | Palliative (P) | 2015-08-12 | 2016-03-27 | BR14 TRIAL | N | N | 210042047 | CYCLOPHOSPHAMIDE + ETOPOSIDE + PROCARBAZINE |
| 210031612 | 210028269 | 1.61 | null | Adjuvant (A) | 2015-06-06 | 2015-06-06 | PIXANTRONE | 02 | N | 210012122 | CYCLOPHOSPHAMIDE HIGH DOSE |
| 210031613 | 210014065 | 1.63 | 55 | Disease modification (D) | null | 2018-02-28 | TRASTUZUMAB | N | N | 210024514 | RUXOLITINIB |
| 210031614 | 210014068 | 0 | 64.4 | Curative (C) | 2018-12-11 | 2018-12-16 | AML 18 TRIAL | N | null | 210025987 | BEAM |
| 210031615 | 210033735 | 1.67 | 20.3 | Palliative (P) | 2016-03-20 | 2016-12-09 | CYCLOPHOSPHAMIDE + CYTARABINE | 02 | N | 210029013 | ALEMTUZUMAB + ETOPOSIDE |
| 210031616 | 210033735 | 1.88 | 117.5 | Palliative (P) | 2017-09-03 | 2017-09-08 | CLARITY Trial | 02 | N | 210029013 | CYCLO + FLUDARABINE + RITUXIMAB |
| 210031617 | 210014070 | 1.79 | null | Curative (C) | 2019-07-11 | 2019-08-11 | CNS Medbl Std Risk Maint Cisplatin | N | N | 210030920 | LENALIDOMIDE |
| 210031618 | 210022767 | 0 | 60.8 | Adjuvant (A) | 2017-01-17 | 2017-01-17 | CLL210 TRIAL | N | N | 210032826 | AML19 TRIAL |
| 210031619 | 210014077 | 1.75 | 83.4 | Disease modification (D) | 2018-01-31 | 2018-01-31 | Cytarabine HD + Methotrexate HD | 2 | N | 210032863 | CETUXIMAB + IRINOTECAN |
| 210031620 | 210028274 | null | null | Palliative (P) | 2017-03-28 | 2017-10-06 | Maintenance Therapy ALL | N | null | 210034307 | ICE |
| 210031621 | 210033737 | 1.8 | 26.8 | Palliative (P) | 2017-07-07 | 2017-07-07 | Capecitabine | 2 | null | 210039936 | DOXORUBICIN |
| 210031622 | 210014089 | 1.56 | 98 | Disease modification (D) | null | 2019-06-03 | CISPLATIN + LOMUSTINE + VINCRISTINE | null | null | 210041640 | UKALL 60+ TRIAL |
| 210031623 | 210014093 | 1.57 | 78.5 | Palliative (P) | 2019-12-24 | 2019-12-27 | CNS Medbl Std Risk Maint Cisplatin | N | N | 210013365 | ALEMTUZUMAB + CYCLO + FLUDARABINE |